FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:140-151 January 10, 2008 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Paul, E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mTOR). The drug sirolimus suppresses mTOR signaling.

Methods We conducted a 24-month, nonrandomized, open-label trial to determine whether sirolimus reduces the angiomyolipoma volume in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. Sirolimus was administered for the first 12 months only. Serial magnetic resonance imaging of angiomyolipomas and brain lesions, computed tomography of lung cysts, and pulmonary-function tests were performed.

Results Of the 25 patients enrolled, 20 completed the 12-month evaluation, and 18 completed the 24-month evaluation. The mean (±SD) angiomyolipoma volume at 12 months was 53.2±26.6% of the baseline value (P<0.001) and at 24 months was 85.9±28.5% of the baseline value (P=0.005). At 24 months, five patients had a persistent reduction in the angiomyolipoma volume of 30% or more. During the period of sirolimus therapy, among patients with lymphangioleiomyomatosis, the mean forced expiratory volume in 1 second (FEV₁) increased by 118±330 ml (P=0.06), the forced vital capacity (FVC) increased by 390±570 ml (P<0.001), and the residual volume decreased by 439±493 ml (P=0.02), as compared with baseline values. One year after sirolimus was discontinued, the FEV₁ was 62±411 ml above the baseline value, the FVC was 346±712 ml above the baseline value, and the residual volume was 333±570 ml below the baseline value; cerebral lesions were unchanged. Five patients had six serious adverse events while receiving sirolimus, including diarrhea, pyelonephritis, stomatitis, and respiratory infections.

Conclusions Angiomyolipomas regressed somewhat during sirolimus therapy but tended to increase in volume after the therapy was stopped. Some patients with lymphangioleiomyomatosis had improvement in spirometric measurements and gas trapping that persisted after treatment. Suppression of mTOR signaling might constitute an ameliorative treatment in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. (ClinicalTrials.gov number, NCT00457808 [ClinicalTrials.gov] .)

Source Information

From the Divisions of Nephrology and Hypertension (J.J.B.), Pulmonary Medicine (L.R.Y.), Neurology (G.C., J.M.L., D.N.F.), Radiology (V.J.S., T.L., A.S.B.), and Biostatistics (J.B., S.S.), Cincinnati Children's Hospital Medical Center; and the Division of Pulmonary and Critical Care, University of Cincinnati College of Medicine (F.X.M., L.R.Y., J.M.E.) — both in Cincinnati.

Drs. McCormack, Young, and Franz contributed equally to the article.

Address reprint requests to Dr. Bissler at Cincinnati Children's Hospital Medical Center, MLC 7022, 3333 Burnet Ave., Cincinnati, OH 45229-3039, or at john.bissler{at}cchmc.org.

Full Text of this Article

Related Letters:

Sirolimus for Lymphangioleiomyomatosis Lesions
Egan J. J., Remund K. F., Corris P., Bissler J. J., Young L. R., McCormack F. X.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1963-1964, May 1, 2008. Correspondence

This article has been cited by other articles:

• Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., Shaw, R. J. (2009). mTOR and HIF-1{alpha}-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 106: 11137-11142 [Abstract] [Full Text]  
• Pollizzi, K., Malinowska-Kolodziej, I., Doughty, C., Betz, C., Ma, J., Goto, J., Kwiatkowski, D. J. (2009). A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles. Hum Mol Genet 18: 2378-2387 [Abstract] [Full Text]  
• Bonnet, C. S., Aldred, M., von Ruhland, C., Harris, R., Sandford, R., Cheadle, J. P. (2009). Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18: 2166-2176 [Abstract] [Full Text]  
• Lesma, E., Sirchia, S. M., Ancona, S., Carelli, S., Bosari, S., Ghelma, F., Montanari, E., Di Giulio, A. M., Gorio, A. (2009). The Methylation of the TSC2 Promoter Underlies the Abnormal Growth of TSC2 Angiomyolipoma-Derived Smooth Muscle Cells. Am. J. Pathol. 174: 2150-2159 [Abstract] [Full Text]  
• Meric-Bernstam, F., Gonzalez-Angulo, A. M. (2009). Targeting the mTOR Signaling Network for Cancer Therapy. JCO 27: 2278-2287 [Abstract] [Full Text]  
• Inoki, K., Guan, K.-L. (2009). Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 18: R94-R100 [Abstract] [Full Text]  
• Way, S. W., McKenna, J. III, Mietzsch, U., Reith, R. M., Wu, H. C.-j., Gambello, M. J. (2009). Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 18: 1252-1265 [Abstract] [Full Text]  
• Han, S., Polizzano, C., Nielsen, G. P., Hornicek, F. J., Rosenberg, A. E., Ramesh, V. (2009). Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas. Clin. Cancer Res. 15: 1940-1946 [Abstract] [Full Text]  
• Dennis, P. A. (2009). Rapamycin for Chemoprevention of Upper Aerodigestive Tract Cancers. Cancer Prevention Research 2: 7-9 [Full Text]  
• Ohara, T., Oto, T., Miyoshi, K., Tao, H., Yamane, M., Toyooka, S., Okazaki, M., Date, H., Sano, Y. (2008). Sirolimus Ameliorated Post Lung Transplant Chylothorax in Lymphangioleiomyomatosis. Ann. Thorac. Surg. 86: e7-e8 [Abstract] [Full Text]  
• Kim, R., Meyer, K. C. (2008). Review: Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2: 319-338 [Abstract]  
• Koenig, M. K., Butler, I. J., Northrup, H. (2008). Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex. J Child Neurol 23: 1238-1239 [Abstract]  
• Rosner, M., Hengstschlager, M. (2008). Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 17: 2934-2948 [Abstract] [Full Text]  
• Edelstein, C. L. (2008). Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease. CJASN 3: 1219-1226 [Abstract] [Full Text]  
• Cowley, B. D. Jr. (2008). Introduction: New Insights, Treatments, and Management Strategies for ADPKD. CJASN 3: 1195-1196 [Full Text]  
• Egan, J. J., Remund, K. F., Corris, P., Bissler, J. J., Young, L. R., McCormack, F. X. (2008). Sirolimus for Lymphangioleiomyomatosis Lesions. NEJM 358: 1963-1964 [Full Text]  
• (2008). Sirolimus for Angiomyolipoma and Lymphangioleiomyomatosis. JWatch Neurology 2008: 1-1 [Full Text]  
• McCormack, F. X. (2008). Lymphangioleiomyomatosis: A Clinical Update. Chest 133: 507-516 [Abstract] [Full Text]  
• Paul, E., Thiele, E. (2008). Efficacy of Sirolimus in Treating Tuberous Sclerosis and Lymphangioleiomyomatosis. NEJM 358: 190-192 [Full Text]